TrialPapillomavirus research (Amsterdam, Netherlands)2020

Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.

Sven-Eric Olsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.